Merus kündigt Veröffentlichung eines Abstracts zu Zenocutuzumab bei Patienten mit Krebsarten mit NRG1-Fusionen (NRG1+) auf der Jahreshauptversammlung 2021 der American Society of Clinical Oncology (ASCO) an

NEXT STORY
Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
PREV STORY
Affimed Announces Virtual Annual General Meeting of Shareholders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Merus kündigt Veröffentlichung eines Abstracts zu Zenocutuzumab bei Patienten mit Krebsarten mit NRG1-Fusionen (NRG1+) auf der Jahreshauptversammlung 2021 der American Society of Clinical Oncology (ASCO) an

NEXT STORY
Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
PREV STORY
Affimed Announces Virtual Annual General Meeting of Shareholders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update

2Q’17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S. ...

author_avatar
NASDAQ Market News

The German Sleep Society (DGSM) Recognizes PAT™ based Technology in its New Sleep-Related Breathing Disorders Guidelines, Further Benefitting Itamar Medical’s Approach to Sleep Apnea Diagnosis

author_avatar
NASDAQ Market News

Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies

author_avatar
NASDAQ Market News